272 related articles for article (PubMed ID: 33342311)
1. An updated patent review of autotaxin inhibitors (2017-present).
Tan Z; Lei H; Guo M; Chen Y; Zhai X
Expert Opin Ther Pat; 2021 May; 31(5):421-434. PubMed ID: 33342311
[TBL] [Abstract][Full Text] [Related]
2. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
3. Autotaxin inhibitors: a patent review.
Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
[TBL] [Abstract][Full Text] [Related]
4. Nucleotide pyrophosphatase/phosphodiesterases (NPPs) including NPP1 and NPP2/ ATX as important drug targets: A patent review (2015-2020).
Bano S; Al-Rashida M; Alharthy RD; Khan IA; Iqbal J
Expert Opin Ther Pat; 2022 Jul; 32(7):743-751. PubMed ID: 35333684
[TBL] [Abstract][Full Text] [Related]
5. alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors.
Cui P; McCalmont WF; Tomsig JL; Lynch KR; Macdonald TL
Bioorg Med Chem; 2008 Mar; 16(5):2212-25. PubMed ID: 18082408
[TBL] [Abstract][Full Text] [Related]
6. Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials.
Matralis AN; Afantitis A; Aidinis V
Med Res Rev; 2019 May; 39(3):976-1013. PubMed ID: 30462853
[TBL] [Abstract][Full Text] [Related]
7. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
[TBL] [Abstract][Full Text] [Related]
8. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
[TBL] [Abstract][Full Text] [Related]
9. Identification of Potent
Kawaguchi M; Okabe T; Okudaira S; Hama K; Kano K; Nishimasu H; Nakagawa H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
J Med Chem; 2020 Mar; 63(6):3188-3204. PubMed ID: 32134652
[TBL] [Abstract][Full Text] [Related]
10. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
[TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation.
Balupuri A; Lee MH; Chae S; Jung E; Yoon W; Kim Y; Son SJ; Ryu J; Kang DH; Yang YJ; You JN; Kwon H; Jeong JW; Koo TS; Lee DY; Kang NS
Eur J Med Chem; 2018 Mar; 148():397-409. PubMed ID: 29477073
[TBL] [Abstract][Full Text] [Related]
12. Benzoxaboroles-Novel Autotaxin Inhibitors.
Kraljić K; Jelić D; Žiher D; Cvrtila A; Dragojević S; Sinković V; Mesić M
Molecules; 2019 Sep; 24(19):. PubMed ID: 31547058
[TBL] [Abstract][Full Text] [Related]
13. Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.
Joncour A; Desroy N; Housseman C; Bock X; Bienvenu N; Cherel L; Labeguere V; Peixoto C; Annoot D; Lepissier L; Heiermann J; Hengeveld WJ; Pilzak G; Monjardet A; Wakselman E; Roncoroni V; Le Tallec S; Galien R; David C; Vandervoort N; Christophe T; Conrath K; Jans M; Wohlkonig A; Soror S; Steyaert J; Touitou R; Fleury D; Vercheval L; Mollat P; Triballeau N; van der Aar E; Brys R; Heckmann B
J Med Chem; 2017 Sep; 60(17):7371-7392. PubMed ID: 28731719
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors.
Lei H; Wang X; Zhao G; Li T; Cui Y; Wu H; Yang J; Jiang N; Zhai X
Eur J Med Chem; 2022 Jun; 236():114307. PubMed ID: 35436669
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, docking and biological evaluation of 4-phenyl-thiazole derivatives as autotaxin (ATX) inhibitors.
Balupuri A; Lee DY; Lee MH; Chae S; Jung E; Kim Y; Ryu J; Kang NS
Bioorg Med Chem Lett; 2017 Sep; 27(17):4156-4164. PubMed ID: 28743508
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophoric Site Identification and Inhibitor Design for Autotaxin.
Lee MH; Lee DY; Balupuri A; Jeong JW; Kang NS
Molecules; 2019 Aug; 24(15):. PubMed ID: 31374894
[TBL] [Abstract][Full Text] [Related]
17. Hybrid imidazo[1,2-a]pyridine analogs as potent ATX inhibitors with concrete in vivo antifibrosis effect.
Li T; Lei H; Yang J; Cao Z; Yang Y; Liu Z; Sun R; Yang X; Zhai X
Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200171. PubMed ID: 35661405
[TBL] [Abstract][Full Text] [Related]
18. Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.
Fells JI; Lee SC; Fujiwara Y; Norman DD; Lim KG; Tsukahara R; Liu J; Patil R; Miller DD; Kirby RJ; Nelson S; Seibel W; Papoian R; Parrill AL; Baker DL; Bittman R; Tigyi G
Mol Pharmacol; 2013 Sep; 84(3):415-24. PubMed ID: 23793291
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of 2,4-dihydropyrano[2,3-c]pyrazole derivatives as autotaxin inhibitors.
Pantsar T; Singha P; Nevalainen TJ; Koshevoy I; Leppänen J; Poso A; Niskanen JMA; Pasonen-Seppänen S; Savinainen JR; Laitinen T; Laitinen JT
Eur J Pharm Sci; 2017 Sep; 107():97-111. PubMed ID: 28687529
[TBL] [Abstract][Full Text] [Related]
20. Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model.
Lei H; Cao Z; Wu H; Li T; Wang X; Chen Y; Ma E; Sun L; Zhai X
Eur J Med Chem; 2022 Jan; 227():113951. PubMed ID: 34742015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]